Acute Puromycin Aminonucleoside (PAN) Model

Focal and segmental glomerulosclerosis (FSG) is a chronic glomerulopathy whose pathogenesis remains poorly understood. It is estimated that FSG accounts for 2.5% of all causes for chronic kidney disease with difficulties to deal with. Puromycin aminonucleoside induced glomerulosclerosis is a less expensive and time-saving model which is often characterized by nephrotic syndromes with podocyte lesions, mesangial expansion, endothelial swelling obliterating the capillary lumen, and increased glomerular volume.

Creative Bioarray focuses on drug research and development services and helps customers evaluate the drug efficacy and study the associated pathological mechanisms of FSG by acute puromycin aminonucleoside (PAN) model.

Our capabilities

  • We utilize Acute Puromycin Aminonucleoside (PAN) Model to test the efficacy of drug candidates targeting FSG.
  • We assess the severity of lesion through glomerular damage score system.
  • We detect the infiltration of monocyte/macrophage via IHC.
  • We evaluate various cytokines through IHC, ELISA, etc.

Assays available

  • PK/PD blood collections
  • Detection of blood creatinine
  • BUN
  • Proteinuria
  • Histopathological evaluation

With extensive experience in the field of FSG, we are confident to help you to overcome any upcoming challenges. Our experts are fully capable of customizing our protocols and assays to meet your specific needs. With our help, we wish to facilitate your research with high efficiency.

Study examples

Urinary protein excretion (mg/24 h) of the groups after 30, 60, and 90 days.Figure. 1. Urinary protein excretion (mg/24 h) of the groups after 30, 60, and 90 days.

Fibronectin immunostaining in renal cortex from the groups: Control (A), LMWH (B), PAN (C), and PAN+LMWH (D) (magnification 400). Figure. 2. Fibronectin immunostaining in renal cortex from the groups: Control (A), LMWH (B), PAN (C), and PAN+LMWH (D) (magnification 400).

Quotation and ordering

If you have any special needs or questions regarding our services, please feel free to contact us. We look forward to cooperating with you in the future.

Reference

  1. Santos A M R D, Olveira A V D, et al. Low molecular weight heparin in the treatment of puromycin-induced nephrosis[J]. Pathology Research & Practice, 2006, 202(3):157-163.

For research use only. Not for any other purpose.